Fineline Cube

Follow:
14778 Articles
Roche's Vabysmo Receives NMPA Approval for Macular Edema Treatments in China
CompanyDrug

Roche’s Vabysmo Receives NMPA Approval for Macular Edema Treatments in China

Intas Pharmaceuticals Receives FDA Approval for Biosimilar Stelara, Expanding Treatment Options for Autoimmune Diseases
CompanyDrug

Intas Pharmaceuticals Receives FDA Approval for Biosimilar Stelara, Expanding Treatment Options for Autoimmune Diseases

Beijing Aims to Build a Leading Cell and Gene Therapy Hub by 2026 with New Action Plan
Policy / Regulatory

Beijing Aims to Build a Leading Cell and Gene Therapy Hub by 2026 with New Action Plan

RemeGen's Disitamab Vedotin Receives Priority Review for New Indication in Breast Cancer by China's NMPA
CompanyDrug

RemeGen’s Disitamab Vedotin Receives Priority Review for New Indication in Breast Cancer by China’s NMPA

Lundbeck Secures Rights to Bexicaserin with Acquisition of Longboard Pharmaceuticals
CompanyDeals

Lundbeck Secures Rights to Bexicaserin with Acquisition of Longboard Pharmaceuticals

Stemirna Therapeutics, Once a Leading mRNA Developer in China, Enters Bankruptcy Proceedings
Company

Stemirna Therapeutics, Once a Leading mRNA Developer in China, Enters Bankruptcy Proceedings

Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders
Legal / IP

Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders

AstraZeneca and Daiichi Sankyo’s Enhertu Receives Fourth Indication Approval in China
CompanyDrug

AstraZeneca and Daiichi Sankyo’s Enhertu Receives Fourth Indication Approval in China

Bristol-Myers Squibb's Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China
CompanyDrug

BMS’s Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China

Sichuan Biokin Pharmaceutical Gets FDA Approval for CD33-Targeting ADC in Acute Myeloid Leukemia
CompanyDrug

Sichuan Biokin Pharmaceutical Gets FDA Approval for CD33-Targeting ADC in Acute Myeloid Leukemia

iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies
CompanyDeals

iRegene Therapeutics Secures Over USD 14 Million in Series B Financing to Advance Cell Therapies

BrightGene's BGM0504 Shows Promise in Phase II Obesity Study Without Diabetes
CompanyDrug

BrightGene’s BGM0504 Shows Promise in Phase II Obesity Study Without Diabetes